Is Aimovig in shortage in 2026? Get the latest on Aimovig (Erenumab) availability, pricing, and what patients can do to keep their migraine treatment on track.
If your pharmacy recently told you they can't fill your Aimovig (Erenumab-aooe) prescription, your first thought was probably: "Is there a shortage?" It's a fair question — and one that a lot of migraine patients are asking right now.
Here's the short answer: As of early 2026, Aimovig is not listed on the FDA Drug Shortage Database. There is no official, nationwide shortage of this medication.
But that doesn't mean every patient can walk into a pharmacy and walk out with Aimovig in hand. The reality is more nuanced — and understanding the difference between a shortage and an access problem can help you take the right steps to get your medication.
Yes, for some patients. Even without a formal shortage, Aimovig can be difficult to fill for several reasons:
In 2023, some patients in the U.S. reported temporary difficulty filling their Aimovig prescriptions at certain pharmacies. These were distribution-level disruptions — not a manufacturing shortage — and they eventually resolved. Similar intermittent reports have surfaced since then, particularly around insurance plan changes at the start of the year.
For a deeper dive into the root causes, read why Aimovig is so hard to find.
Unlike a common generic medication that every pharmacy keeps on the shelf, Aimovig flows through a narrow distribution pipeline. It goes from Amgen to specialty distributors to specialty pharmacies, then to you. Each step in this chain introduces potential delays — especially if your insurance plan requires you to use a specific specialty pharmacy.
Most insurance plans require prior authorization before they'll cover Aimovig. Many also require step therapy, meaning you have to try and fail cheaper medications first. If your prior auth expires or your insurance plan changes (common in January), you may suddenly lose access until the paperwork is renewed.
Aimovig is a biologic with no biosimilar competitors. With only one manufacturer and one product, there's no fallback option within the same formulation. This is different from medications like Humira, which now have biosimilar alternatives that ease supply constraints.
Cost continues to be a significant factor in access:
For detailed cost-saving strategies, read our guide: How to save money on Aimovig in 2026.
The migraine treatment landscape has expanded significantly since Aimovig was first approved in 2018. If you're having trouble accessing Aimovig, it's worth knowing about the other FDA-approved CGRP inhibitors:
Each of these works through the CGRP pathway and is approved for migraine prevention. Your doctor can help determine which one fits your clinical profile and insurance coverage. Learn more in our guide to Aimovig alternatives.
If you need Aimovig and your pharmacy doesn't have it, here's what to do:
For more detailed strategies, read our full article: How to find Aimovig in stock near you.
Aimovig isn't in a formal shortage in 2026, but the combination of specialty pharmacy distribution, insurance hurdles, and a single-manufacturer supply chain means it's not always easy to get. The good news is that tools like Medfinder, manufacturer support programs, and a growing number of CGRP alternatives give you real options.
Stay proactive. Plan your refills ahead of time. And if you're hitting a wall, don't suffer through migraines in silence — talk to your doctor about what's next.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
